• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research

01/03/2017 by Intellectual Property Watch 2 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Big Pharma wants to develop treatments for rare diseases, with government support. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week launched a new report describing policy priorities to increase research and development into rare diseases.

Rare diseases are conditions which affect very small numbers of people. Currently between 5,000 and 8,000 rare diseases have been identified. The day 28 February was called Rare Diseases Day.

IFPMA issued a report entitled, “Rare diseases: shaping a future with no one left behind.” It is “a new resource to understand key challenges in areas such as R&D, clinical trials, diagnosis, and access to treatment,” IFPMA said in a press release.

According to the report, “Traditionally, research and development of treatments for rare diseases has been neglected in favour of more common diseases. However, in the last twenty years, concerted public policy efforts have led to a marked improvement in our understanding of many rare diseases and availability of effective treatment options.”

Rare diseases pose particular challenges for research and clinical development, the report said. This is due to the small numbers of patients, limited epidemiological data on the natural history of many rare diseases, and all stages of research and development being more challenging and lengthy than for more common diseases, it said.

The report provides a set of policy objectives, such as that continued R&D be promoted, “building political commitment to drive research, innovation and policies for rare diseases and innovation and policies for rare diseases, and increasing collaborative research efforts to enhance scientific understanding of all rare diseases.

The pharma industry group also called for sustainable access to diagnosis, treatment and care, improving the workforce and infrastructure to treat rare diseases, and developing and strengthening legislation that enhances access to orphan drugs, which are treatments for rare diseases.

Separately, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) today called for increased collaboration to develop solutions for rare disease patients. Despite the success of the European Regulation on Orphan Medicinal Products in encouraging the development of new therapies for rare diseases, accessibility varies between European Union member states, EUCOPE said in a press release.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Europe, Health & IP, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy

Trackbacks

  1. Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research – WebLegal says:
    01/03/2017 at 9:50 am

    […] a new report describing policy priorities to increase research and development into rare diseases. Go to Source Author: Catherine […]

    Reply
  2. Links 1/3/2017: Q4OS 1.8.3, Lakka 2.0 RC1 | Techrights says:
    02/03/2017 at 1:09 am

    […] Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research [Ed: Sounds like this cartel is urging politicians to give it taxpayers' money for monopolies and patents, to hold lives hostage] […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2019 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.